| For: | Gosnell JM, Golovko G, Arroyave E, Moghe A, Kueht ML, Saldarriaga OA, McKinney KH, Stevenson HL, Ferguson MR. Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study. World J Diabetes 2024; 15(5): 886-897 [PMID: 38766421 DOI: 10.4239/wjd.v15.i5.886] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v15/i5/886.htm |
| Number | Citing Articles |
| 1 |
Nicholas A. Cumpian, Julio A. Gutierrez, William Wu, Sammy Saab. Targeting MASLD and MASH in the US Hispanic/Latino Population. JAMA Internal Medicine 2025; 185(11): 1376 doi: 10.1001/jamainternmed.2025.4769
|
| 2 |
Lucy C. Taylor, Gertrude Arthur, Marcella de Carvalho Cruz, David E. Stec, Olufunto O. Badmus. Contribution of Sex Differences to Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD). International Journal of Translational Medicine 2024; 4(4): 782 doi: 10.3390/ijtm4040052
|
| 3 |
Ruey-Shyang Soong, Wan-Ming Chen, An-Tzu Jao, Ming-Che Lee, Szu-Yuan Wu, Chih-Lang Lin. SGLT2 inhibitors and the risk of hepatocellular carcinoma in patients with MASLD and Type 2 diabetes. Diabetes & Metabolism 2025; 51(6): 101698 doi: 10.1016/j.diabet.2025.101698
|
| 4 |
Ze-Xu Zheng, Shu-Min Huang. Heterogeneous outcomes in metabolic dysfunction–associated steatotic liver disease/steatohepatitis with type 2 diabetes: Rethinking risk and management approaches. World Journal of Clinical Cases 2025; 13(29): 110771 doi: 10.12998/wjcc.v13.i29.110771
|
